Cost & Insurance

Leftover FSA or HSA Money at Year-End: Can It Cover Stem Cell Treatment Abroad?

The honest answer is "possibly, but nobody can promise it." Here is what the IRS rules actually say, where they go quiet, and why a year-end deadline should never make a medical decision for you.

October 31, 2026 · 10 min read · Last checked: October 31, 2026

Leftover health-account money creates pressure every fall. If you have been reading about stem cell treatment in Colombia, it is natural to wonder whether that balance could help pay for it.

The IRS rules give a partial answer. They define medical care, exclude illegal treatments, and restrict drugs obtained abroad. They do not name stem cell products or say how an unapproved product given legally in another country should be treated. That decision sits with your plan administrator, and possibly your tax professional.

We already have a broader guide to using an HSA or FSA for stem cell therapy. This article focuses on the year-end question and on the parts of the rules that apply when care happens outside the US.

What actually expires at year-end

The two account types behave very differently. Mixing them up is the most common source of unnecessary urgency.

For comparison, the 2025 carryover cap was $660, according to Publication 969 (2025). Your own plan's documents control which option applies to you and any lower limit it sets.

What the IRS counts as medical care

IRS Publication 502 (2025) defines medical expenses as the costs of diagnosis, cure, mitigation, treatment or prevention of disease. The care must be primarily to alleviate or prevent a physical or mental disability or illness.

Expenses that are merely good for general health do not qualify. The publication gives vitamins and a vacation as examples.

Cosmetic procedures

Pub 502 says cosmetic surgery generally does not qualify. It defines it as any procedure aimed at improving appearance, with exceptions for deformities from a congenital abnormality, injury or disfiguring disease.

That matters here because many clinics market stem cell products for anti-aging, skin or hair. Those uses are hard to square with the IRS definition.

Travel and lodging

Transportation can count only if it is primarily for, and essential to, medical care. Lodging has four conditions, and all must be met.

1. The lodging is primarily for and essential to medical care.
2. A doctor provides the care in a licensed hospital or an equivalent facility.
3. The lodging is not lavish or extravagant.
4. There is no significant element of personal pleasure, recreation or vacation.

Pub 502 caps lodging at $50 per night per person. A parent traveling with a sick child can include up to $100 per night.

The Pub 502 rules that matter abroad

We read the full 2025 edition of Publication 502. We did not find a general rule excluding care simply because it is received outside the US. Three specific rules do apply, and each one is relevant to stem cell products.

1. Drugs from other countries

In general, Pub 502 says you cannot include the cost of a prescribed drug brought in or shipped from another country. You can include a prescribed drug bought and used in another country only if the drug is legal in both that country and the United States.

2. Illegal operations and treatments

Pub 502 says you cannot include amounts paid for illegal operations, treatments or controlled substances. This applies whether a licensed or unlicensed practitioner provided or prescribed them.

3. Controlled substances

Substances that are not legal under federal law do not count, even where state law allows them. This rule is unlikely to apply to cell products, but it shows the IRS looks to federal law.

What is genuinely unclear

This is the part most articles skip. We could not find IRS guidance that settles any of the following points. Treat them as open questions, not as answers.

• Product status. The FDA says most stem cell and exosome products sold for orthopedic, neurological and anti-aging uses are not approved in the US. Pub 502 does not say how that interacts with its rule that a drug used abroad must be legal in both countries.
• Unproven care. Pub 502, as we read it, does not mention experimental or unproven treatments at all. It neither includes nor excludes them by name.
• Your plan's rules. Pub 969 says FSA eligible expenses are the ones specified in the plan. A plan can be narrower than the tax law.
• Documentation abroad. FSAs need a written statement from an independent third party. Whether a foreign clinic's invoice satisfies your plan is up to the administrator.

Because of these gaps, nobody can tell you in advance that your claim will be paid. Anyone who promises it is guessing, including a clinic.

The timing trap: deposits and future care

Year-end spending usually means paying for something now. That runs into two IRS rules.

First, Publication 969 says an FSA cannot reimburse advance or projected expenses. FSA reimbursements must be for expenses incurred during the period of coverage. A deposit paid in December for treatment in March may not count as a 2026 expense.

Second, if you itemize medical expenses on your tax return instead, Pub 502 says you can generally include only expenses paid that year, not payments for care in a future year. It also notes that this paid-this-year rule is not the test for FSA reimbursement. That is one more reason to ask your administrator rather than rely on general rules.

If your plan has a grace period, care received during that window may be payable from last year's balance. If your plan has a carryover instead, up to $680 of 2026 money may stay available, subject to your plan's terms.

How to ask your plan administrator

Ask before you pay a deposit or book travel. A written answer protects you; a phone conversation does not.

1. Find your plan type. Check whether you have an FSA, an HSA, a limited-purpose FSA or an HRA. The rules differ.
2. Confirm your deadlines. Ask for your plan year end, and whether your FSA offers a carryover, a grace period or neither.
3. Describe the treatment precisely. Name the procedure, the product, the country, and the diagnosis it is meant to treat.
4. Ask about foreign care and products. Ask specifically how the plan treats care received abroad and products not approved by the FDA.
5. Ask what documents they need. Ask whether your plan requires a letter from your own doctor, translations, or a specific claim form.
6. Get the answer in writing. Save the email or letter with your records. The ISSCR's patient questions make the same point: ask what your insurance will cover and how to get pre-approval to avoid unexpected bills.

For HSAs, Publication 969 puts record-keeping on you. You must be able to show distributions went to qualified medical expenses that were not paid from another source or itemized. You do not send these records with your return.

To compare costs line by line, see how to compare two clinic quotes side by side.

Don't let a deadline decide

The math rarely favors rushing. Depending on your plan, an FSA balance above the carryover cap may be forfeited. That loss is real, but it is capped. A rushed decision about an unproven treatment carries risks that are not capped.

The FDA lists serious harms linked to unapproved regenerative products, including infections, blindness, tumor formation and immune reactions. Treatment abroad also means travel, follow-up care at home and costs your insurance may not cover. Our travel insurance guide covers that side.

If you have leftover FSA money and no clear answer yet, spending it on conventional eligible care you already need may be the safer use. Discuss the treatment itself with your own physician first, on its own schedule.

Disclosure: If you ask us for provider options, your inquiry may be shared with up to three providers, and participating providers may compensate our network.